Osteoporosis is a major public health problem and the most obvious preventive strategy, hormone replacement therapy, has lost favor due to recent findings of the Women's Health Initiative regarding increased risks of breast cancer and cardiovascular disease. Resveratrol, a naturally occurring compound possessing estrogenic activity, is thought to have considerable potential for therapy of osteoporosis. In the present study, resveratrol was found to exhibit bone-protective effects equivalent to those exerted by hormone replacement therapy and decrease the risk of breast cancer in the in vivo and in vitro models. Forkhead proteins were found to be essential for both effects of resveratrol. The bone-protective effect was attributable to induction of bone morphogenetic protein-2 through Src kinase-dependent estrogen receptor activation and FOXA1 is required for resveratrol-induced estrogen receptor-dependent bone morphogenetic protein-2 expression. The tumor-suppressive effects of resveratrol were the consequence of Akt inactivation-mediated FOXO3a nuclear accumulation and activation. Resveratrol is therefore anticipated to be highly effective in management of postmenopausal osteoporosis without an increased risk of breast cancer. © 2007 by The American Society for Biochemistry and Molecular Biology, Inc.
CITATION STYLE
Su, J. L., Yang, C. Y., Zhao, M., Kuo, M. L., & Yen, M. L. (2007). Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. Journal of Biological Chemistry, 282(27), 19385–19398. https://doi.org/10.1074/jbc.M702452200
Mendeley helps you to discover research relevant for your work.